Pharmeasy
-16%
est. 2Y upside i
Rank
#2672
Sector
HealthTech
Est. Liquidity
~3Y
Data Quality
Data: MediumDespite a low entry valuation of $456M, PharmEasy faces severe headwinds including a heavy preference stack ($2.34B total funding), low growth (~3.7%), and intense competition.
Last updated: July 21, 2026
If PharmEasy achieves an IPO and returns to growth, valuation could recover to a modest revenue multiple of ~1.24x, yielding 100% upside from current secondary valuation. However, low growth and intense competition limit further upside.
In the base case, revenue grows slowly to $738M, and the exit multiple stabilizes at 1x revenue (still below public comps) as the company restructures. After 20% dilution from a necessary capital raise, upside is 42%.
In the bear case, continued losses and competitive pressure drive multiple contraction to 0.4x revenue, implying a $295M exit, well below $2.34B in preferred stock. Common equity is wiped out, yielding -100%.
Preference Stack Risk
severeFunding Intensity
33300%Total funding of $2.34B vs entry valuation of $456M results in a 513% preference overhang, meaning common stock has no residual value until exit exceeds $2.34B.
Dilution Risk
highGiven negative cash flow and low growth, a dilutive equity raise within 24 months is probable, estimated at 20% dilution.
Secondary Liquidity
limitedSecondary market implies a 36% discount to the last primary round, indicating limited liquidity and downward pressure.
Questions to Ask at the Interview
Strategic questions based on Pharmeasy's data — designed to show you've done your homework.
- 1
“How will PharmEasy differentiate from well-funded incumbents like Tata 1mg and Amazon Pharmacy?”
- 2
“What is the path to profitability given the current gross margin of 19.8% and low growth?”
- 3
“Given the company's valuation drop and debt default, what is the long-term equity value for early employees?”
Community
Valuation Sentiment
Our model estimates -16% upside. What do you think?
Anonymous. Do not share material non-public information.
Community Discussion
Comments are reviewed before they appear publicly.
Loading comments...
Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.